A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid Leukemia
Samarpana Chakraborty, Claudia Morganti, Kimberly S. Zaldana, Bianca Rivera-Peña, H. Zhang, Divij Verma, Nadege Gitego, Feiyang Ma, Srinivas Aluri, Kith Pradhan, Shanisha Gordon-Mitchell, Ioannis Mantzaris, Mendel Goldfinger, Eric Jay Feldman, Kira Gritsman, , Aditi Shastri
This paper shows that targeting STAT3 with a degrader can overcome Venetoclax resistance in AML by reducing MCL1 and improving mitochondrial function.
Leukemia · Feb 17, 2026Peer-reviewedCancer Biology